Literature DB >> 15549429

Hilar cholangiocarcinoma: resectability and radicality after routine diagnostic imaging.

Gerd Otto1, Bernd Romaneehsen, Maria Hoppe-Lotichius, Fernando Bittinger.   

Abstract

BACKGROUND/
PURPOSE: En-bloc resection has contributed to the improvement of long-term survival in patients with hilar cholangiocarcinoma. In addition, attenuation of intraoperative traumatization of the tumor may decrease tumor spread. The objective of this study was to assess the importance of a routine diagnostic workup for the surgical strategy, radicality, and results in patients with hilar cholangiocarcinoma.
METHODS: Between September 1997 and December 2002, 82 patients with hilar cholangiocarcinoma were treated at our department. Preoperative diagnostic workup included endoscopic retrograde cholangiography (ERC), percutaneous transhepatic cholangiography (PTC), computed tomography (CT), and magnetic resonance imaging (MRI). The results of preoperative and retrospective (blinded) assessment of diagnostic data concerning the tumor growth along the bile ducts were compared with the results of surgery.
RESULTS: The resection rate was 75%, and the hospital mortality, 7%. The prospective assessment of the resection to be performed was correct in 81% of cases. In ERC, magnetic resonance cholangiography (MRC), and PTC, tumor assessment was precise in 29%, 36%, and 53%, of cases, respectively. Overestimation occurred more frequently than underestimation. The 3-year survival of patients with formally curative or palliative en-bloc resection was 61% and 15%, respectively. For the 9 patients with hilar resection, the 3-year survival was 25%. Survival of patients was comparable, regardless of whether their tumor had been correctly assessed or over- or underestimated. In the multivariate analysis, R0 resection was the only significant prognostic factor ( P = 0.011).
CONCLUSIONS: Our routine diagnostic approach led to high resection and survival rates. Obviously a sophisticated diagnostic workup is not an absolute prerequisite for adequate surgery.

Entities:  

Mesh:

Year:  2004        PMID: 15549429     DOI: 10.1007/s00534-004-0912-9

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  8 in total

1.  Addition of hepatectomy decreases liver recurrence and leads to long survival in hilar cholangiocarcinoma.

Authors:  Zheng Shi; Ming-Zhi Yang; Qing-Liang He; Rong-Wen Ou; You-Ting Chen
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

Review 2.  Perihilar cholangiocarcinoma: Current therapy.

Authors:  Wei Zhang; Lu-Nan Yan
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

Review 3.  Diagnostic and surgical approaches in hilar cholangiocarcinoma.

Authors:  Gerd Otto
Journal:  Int J Colorectal Dis       Date:  2006-03-31       Impact factor: 2.571

4.  Post-operative morbidity results in decreased long-term survival after resection for hilar cholangiocarcinoma.

Authors:  Aakash Chauhan; Michael G House; Henry A Pitt; Attila Nakeeb; Thomas J Howard; Nicholas J Zyromski; C Max Schmidt; Chad G Ball; Keith D Lillemoe
Journal:  HPB (Oxford)       Date:  2010-12-07       Impact factor: 3.647

5.  Assessment of hilar and extrahepatic bile duct cancer using multidetector CT: value of adding multiplanar reformations to standard axial images.

Authors:  Jin-Young Choi; Jeong Min Lee; Jae Young Lee; Se Hyung Kim; Min Woo Lee; Joon Koo Han; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2007-05-08       Impact factor: 5.315

6.  Retroportal hepaticojejunostomy for extended resection of hilar bile ducts.

Authors:  Itaru Endo; Mitsutaka Sugita; Hideki Masunari; Kenichi Yoshida; Kazuhisa Takeda; Hitoshi Sekido; Shinji Togo; Hiroshi Shimada
Journal:  J Gastrointest Surg       Date:  2007-10-26       Impact factor: 3.452

7.  Staging cholangiocarcinoma by imaging studies.

Authors:  V Vilgrain
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

8.  Criteria of unresectability and the decision-making process.

Authors:  R D Schulick
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.